Bibliografía
1. Marshall BJ, Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1:1273-5.
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347(15):1175-86.
3. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378 (9790):507-14.
4. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61:1–241.
5. Correa P, Piazuelo MB, Camargo MC. Etiopathogenesis of gastric cancer. Scand J Surg 2006; 95 (4): 218-24.
6. Conteduca V, Sansonno D, Lauletta G, et al. H. pylori infection and gastric cancer: state of the art (review). Int J Oncol 2013; 42(1):5-18.
7. Fuentes-Pananá E, Camorlinga–Ponce M, Maldonado-Bernal C. Infection, inflammation and gastric cancer. Salud Publica Mex 2009; 51 (5): 427-33.
8. Jass JR, Filipe MI. The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981; 13(6):931-9.
9. Quingalahua Flores Aldo, Mendoza Jaime Francisco. Helicobacter pylori, metaplasia intestinal de estómago y cáncer gástrico. Oncología 2004; 14 (1):64-67.
10. Piñol Jiménez Felipe, Paniagua Estévez Manuel, Pérez Sánchez Gloria, et al. Metaplasia intestinal en pacientes con reflujo duodenogástrico y ácidos biliares totales elevados. Rev cubana med 2010; 49(1): 17-32.
11. Kim N, Park YS, Cho SI, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008; 13:245-55.
12. Joo YE, Park HK, Myung DS, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia: a nationwide multicenter prospective study in Korea. Gut Liver 2013; 7(3):303-10.
13. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-40.
14. Kim N, Park RY, Cho SI, et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol 2008; 42: 448-54.
15. Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015; 20(1): 25-40.
16. A review of Human Carcinogens. B. Biological Agents. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 24 February-3 March 2009. IARC Monogr Eval Carcinog Risks Hum 2012; 100(B): 385-423.
17. Micu G, Stăniceanu F, Zurac S, et al. Regression of precancerous epithelial alteration in patients with Helicobacter pylori chronic gastritis. Rom J Intern Med 2010; 48(1):89-99.
18. Lahner E, Bordi C, Cattaruzza MS, et al. Long term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 22: 471 – 481.
19. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011; 83: 253 –260.
20. Vázquez Romero M, Boixeda de Miquel D, Valer López-Fando MP, et al. Intestinal metaplasia: evolution after Helicobacter pylori eradication and influence in the success of eradicating therapy. Rev Esp Enferm Dig 2003; 95(11):781-4.
21. Mearin F, Calleja JL. Defining functional dyspepsia. Rev Esp Enferm Dig 2011; 103 (12): 640-7.
22. Correa P, Bravo L. Investigaciones sobre cáncer gástrico en Nariño. Rev Med Hospital Universitario Departamental de Nariño 2007; 3: 6-12.
23. Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis 2012; 13 (1): 2-9.
24. Salas Caudevilla A. Evaluation of dysplasia in gastrointestinal diseases. Gastroenterol Hepatol 2007; 30(10):602-11.
25. Valdivia Roldán M. Gastritis and gastropathies. Rev Gastroenterol Peru 2011; 31(1):38-48.
26. Peetsalu A, Kirsimägi U, Peetsalu M. Giant peptic ulcer hemorrhages: epidemiology, treatment, and outcome in the teaching hospital of Tartu. Medicina (Kaunas) 2011; 47(1):19-24.
27. Abdo-Francis JM, Uscanga-Domínguez LF, Sobrino-Cossio S, et al. Tercer Consenso Mexicano de Helicobacter pylori. Rev Gastroenterol Mex 2007; 72(3):321-338.
28. Calle Astudillo G, Jerves T, Pesántez L, et al. Utility of routine gastric biopsies and staining with methylene blue in the diagnosis of intestinal metaplasia in patients over 40 years. Acta Gastroenterol Latinoam 2013; 43(3):189-97.
29. Monés J, Rodrigo L, Sancho F, et al . Helicobacter pylori eradication versus one-year maintenance therapy: effect on relapse and gastritis outcome. Rev Esp Enferm Dig 2001; 93(6):372-89.
30. Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, et al. Precancerous conditions after H. pylori eradication: a randomized double blind study in first degree relatives of gastric cancer patients. Arch Iran Med 2012; 15 (11): 664-9.